Product information and disease descriptionPlace of product in therapyDisease description
Epidemiology
11 evidence topics · 9 sources
Azetukalner (XEN1101)
Focal onset seizures
- Manufacturer
- Xenon Pharmaceuticals
- Regulatory submission
- NDA submitted September 2026
- Launch
- Not announced
- Last updated